Onglyza

Onglyza (saxagliptin) is prescribed to treat Type 2 diabetes and has been linked to increased risk of heart failure and pancreatic cancer. In 2014, the New England Journal of Medicine published a study of 16,500 Onglyza users; 27 percent were more likely to be hospitalized for heart failure than those who did not take the drug. In 2013, the Food and Drug Administration warned that people taking Onglyza and similar drugs may be more likely to develop pancreatic cancer. In 2011, a study in Gastroenterology linked a similar drug to a 2.7 times increased risk of pancreatic cancer.

Free Consultation | Lincoln Dangerous Drug Attorneys

Friedman Law Offices is here to help. To schedule a free consultation with our Lincoln, Nebraska, dangerous drug attorneys, contact us online or by calling 866-458-5468 or toll free 888-419-6876.